Vivos Therapeutics (VVOS) Market Capitalization (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Market Capitalization for 7 consecutive years, with $6.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Market Capitalization fell 71.75% year-over-year to $6.5 million in Q2 2026; TTM through Jun 2026 was $6.5 million, a 71.75% decrease from a year earlier, with the FY2025 full-year figure at $18.9 million, down 25.39% from the prior year.
• Market Capitalization was $6.5 million for Q2 2026 at Vivos Therapeutics, down from $15.9 million in the prior quarter.
• Over five years, Market Capitalization peaked at $61.7 million in Q1 2022 and troughed at $5.7 million in Q3 2023.
• A 5-year average of $19.2 million and a median of $15.6 million in 2023 frame the typical range for Market Capitalization.
• Across the five-year window, Market Capitalization tumbled 86.32% in 2023 and surged 206.52% in 2025, its largest moves.
• Over 5 years, Market Capitalization stood at $9.3 million in 2022, then jumped by 63.97% to $15.2 million in 2023, then soared by 66.56% to $25.3 million in 2024, then fell by 25.39% to $18.9 million in 2025, then plunged by 65.31% to $6.5 million in 2026.
• The last three Market Capitalization figures came in at $6.5 million (Q2 2026), $15.9 million (Q1 2026), and $18.9 million (Q4 2025), per Business Quant data.